中国经济网北京1月28日讯圣湘生物(688289.SH)今日收报20.67元，跌幅6.56%。该股目前处于破发状 态。 圣湘生物于2020年8月28日在上交所科创板上市，发行数量为4,000万股，无老股转让，发行价格为50.48 元/股，保荐机构(主承销商)为西部证券（002673）股份有限公司，保荐代表人为李锋、邹扬，联席主承 销商为中信证券股份有限公司。 上市首日，圣湘生物盘中创下上市以来最高价155.55元，为该股上市以来最高价。 圣湘生物募集资金总额为201,920.00万元，募集资金净额为186,926.98万元，较原计划多131,268.98万 元。圣湘生物2020年8月24日披露的招股书显示，公司拟募集资金55,658.00万元，计划用于精准智能分 子诊断系统生产基地项目、研发中心升级建设项目、营销网络及信息化升级建设项目。 圣湘生物上市发行费用为1.50亿元，其中西部证券和中信证券获得保荐及承销费用1.28亿元。 圣湘生物2022年5月26日披露2021年年度权益分派实施公告，根据公司2021年年度股东大会审议通过的 《圣湘生物科技股份有限公司关于2021年度利润分配及资本公积转增股本方案的议 ...

中国经济网北京1月28日讯 百奥泰（688177.SH）今日收报23.82元，跌幅3.95%。目前该股处于破 发状态。 百奥泰首次公开发行股票的发行费用总计8940.02万元，其中，支付给保荐机构中金公司、联席主 承销商广发证券、摩根士丹利华鑫证券的承销及保荐费用7783.02万元。 百奥泰于2020年2月21日在上交所科创板上市，发行价格为32.76元/股，发行股份数量为6000万 股，保荐机构为中国国际金融股份有限公司，保荐代表人为谢显明、赵泽宇，广发证券股份有限公司、 摩根士丹利华鑫证券有限责任公司为联席主承销商。 (责任编辑：魏京婷) 上市首日，百奥泰盘中创下上市以来最高价78.00元/股。 百奥泰首次公开发行股票募集资金总额为19.66亿元，扣除发行费用后募集资金净额为18.76亿元。 百奥泰最终募集资金净额较原计划少1.24亿元。百奥泰2020年2月17日发布的招股说明书显示，该公司 计划募集资金20亿元，分别用于药物研发项目、营销网络建设项目、补充营运资金。 ...

Core Viewpoint - The company Baotai expects to reduce its net loss for the fiscal year 2025 compared to the previous year, projecting a net profit attributable to the parent company of between -280 million yuan and -390 million yuan, which represents a reduction in loss of between 120.30 million yuan and 230.30 million yuan [1] Group 1 - The reduction in loss is attributed to the company's market expansion efforts [1] - Sales of Adalimumab and Tocilizumab have increased, contributing to the improved financial outlook [1] - The launch of Ustekinumab in the United States has also positively impacted revenue through licensing and sales growth [1]

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant contributions from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes the company's self-developed BFA01 adjuvant [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix, indicating a competitive landscape for Ruike's new product [3]

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant holdings from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes a novel adjuvant BFA01 developed by the company [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix [3]

Core Viewpoint - The stock of Innovent Biologics (01801) rose nearly 3% following the announcement that its drug IBI3003 received Fast Track Designation from the FDA for treating relapsed or refractory multiple myeloma [1] Group 1: Company Developments - Innovent Biologics' IBI3003 is a tri-specific antibody targeting GPRC5D/BCMA/CD3, which is currently undergoing Phase I/II clinical trials in China, Australia, and the United States [1] - The FDA's Fast Track Designation is aimed at patients who have undergone at least four lines of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody [1] Group 2: Market Reaction - As of the report, Innovent Biologics' stock price increased by 2.2%, reaching 83.6 HKD, with a trading volume of 204 million HKD [1]

Core Viewpoint - Cinda Biologics (01801) shares rose nearly 3%, currently up 2.2% at HKD 83.6, with a trading volume of HKD 204 million [1] Group 1: Company Developments - Cinda Biologics announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 received Fast Track Designation from the U.S. FDA on January 27, 2026 [1] - The intended indication for IBI3003 is for relapsed or refractory multiple myeloma (R/R MM) patients who have undergone at least four lines of treatment, including a proteasome inhibitor (Pl), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody [1] - IBI3003 is developed using Cinda Biologics' proprietary Sanbody platform and is currently undergoing Phase I/II clinical trials in China, Australia, and soon in the U.S. to explore its efficacy and safety in R/R MM [1]

以下文章来源于阿基米德Biotech ，作者阿基米德君 1月2 0日，历史上一个平淡的日子，唯一的热闹，可能是大寒之日上海飘雪。同日，另 一 场 寒 潮 却 无 声 无 息 ， 恒 生 生 物 科 技 指 数 （ HSHKBIO ） 成 交 额 跌 破 1 0 0 亿 港 币 ， 与 2 0 2 5年最高点相比下降近8 0 %，1 5家港股1 8A公司日成交额不足1 0 0万港币。 创新药在研发主战场外，正在开辟争夺流动性的第二战场。 技术和资本，一体两面，是创新药企的两大属性。早期生物科技没有自我造血功能，全 靠资本输血。成熟创新药企在每一个重要节点，跃升到更高发展阶段，也靠资本支持。 当前，通过港股1 8A通道上市的生物科技企业已达8 5家(含摘B)，还有超过8 0家递表排 队，而流动性却在指缝间溜走。自研能力不够硬，又不做市值管理的公司，等于自动退 出流动性争夺战，被边缘化，被遗忘，直至丧失融资能力。 阿基米德Biotech . 生物科技第三方独立观察，提前感知行业边际变化，客观中立，深入浅出，松弛愉悦 流动性。 作者 / 阿基米德君 来源 / 阿基米德Biotech （ID：ArchimedesBio ...

有望凭借高可及性、优异的疗效成为不逊于pluvicto（50亿美元销售峰值预期）的前列腺癌重磅药物。 （映恩生物） B7-H3 ADC 爆发前夜：III 期密集落地，千亿市场雏形初现 事件：2026年1月26日，clinicaltrials网址显示，BioNTech启动了BNT324（DB-1311）的首个III期临床试验（化疗未 经治的转移性去势抵抗性前列腺癌mCRPC，DB-1311vs多西他赛+泼尼松/泼尼松龙标准治疗方案，主要终点rPFS、 OS），招募736人，2031年1月取得结果。 202 （映恩生物） B7-H3 ADC 爆发前夜：III 期密集落地，千亿市场雏形初现 事件：2026年1月26日，clinicaltrials网址显示，BioNTech启动了BNT324（DB-1311）的首个III期临床试验（化疗未 经治的转移性去势抵抗性前列腺癌mCRPC，DB-1311vs多西他赛+泼尼松/泼尼松龙标准治疗方案，主要终点rPFS、 OS），招募736人，2031年1月取得结果。 2023年映恩生物DB-1311被授权至BioNTech，是第5款进入III期阶段的B7-H3 ADC，具全球商业 ...

消息面上，复宏汉霖宣布，收到国家药监局关于同意注射用HLX43联合HLX07及斯鲁利单抗注射液用 于晚期实体瘤治疗开展临床试验的批准。复宏汉霖计划在条件具备后于中国境内开展该联合治疗方案的 II期临床研究。 复宏汉霖(02696)早盘涨超4%，截至发稿，涨3.48%，报56.5港元，成交额1265.25万港元。 公开资料显示，HLX43为复宏汉霖利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子 与其自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物(ADC)，拟用于治疗晚期/ 转移性实体瘤；HLX07为复宏汉霖自主研发的针对EGFR靶点的创新型生物药，拟用于治疗晚期实体 瘤；斯鲁利单抗注射液为复宏汉霖自主研发的创新型抗PD-1单抗。 ...